Drugs in Dev.								
Cardiology/Vascular Diseases
											
Undisclosed
											
																			
Germany								
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Arkosterol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Arkosterol is a Dietary Supplement drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
September 17, 2025
Lead Product(s) : Arkosterol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Meditrial
Deal Size : Inapplicable
Deal Type : Inapplicable
TRICAV-II Pivotal: TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation.
Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Tricuspid Valve Insufficiency.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 14, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Meditrial
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Lipigon
Deal Size : Undisclosed
Deal Type : Acquisition
Lipigon Pharma buys LNAplus based antisense drug candidates from Secarna Pharma
Details : Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 23, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Lipigon
Deal Size : Undisclosed
Deal Type : Acquisition

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon
Details : Sirolimus is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Coronary Restenosis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 08, 2017
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
